TAKEDA PHARMACEUTICAL COMPANY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,285 JPY | -0.56% |
|
-0.63% | +5.70% |
| 07-17 | Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading | MT |
| 07-17 | Zydus Lifesciences Signs Licensing Pact to Market Vonoprazan in India | MT |
| Sales 2025 * | 4,303B 27.51B 2,118B | Sales 2026 * | 4,364B 27.9B 2,148B | Capitalization | 6,829B 43.67B 3,362B |
|---|---|---|---|---|---|
| Net income 2025 * | 116B 739M 56.93B | Net income 2026 * | 215B 1.38B 106B | EV / Sales 2025 * | 2.54 x |
| Net Debt 2025 * | 4,111B 26.29B 2,024B | Net Debt 2026 * | 3,852B 24.63B 1,897B | EV / Sales 2026 * | 2.45 x |
| P/E ratio 2025 * |
59.2
x | P/E ratio 2026 * |
31.8
x | Employees | 49,281 |
| Yield 2025 * |
4.53% | Yield 2026 * |
4.64% | Free-Float | 99.13% |
More Fundamentals
* Assessed data
More news
Latest transcript on Takeda Pharmaceutical Company Limited
More recommendations
More press releases
| 1 day | -0.56% | ||
| 1 week | -0.63% | ||
| Current month | +2.71% | ||
| 1 month | +5.96% | ||
| 3 months | +4.79% | ||
| 6 months | -2.28% | ||
| Current year | +5.70% |
1 week
4 220.00
4 345.00
1 month
4 003.004 345.00
Current year
4 003.004 494.00
1 year
3 900.004 873.00
3 years
2 993.004 873.00
5 years
2 894.504 873.00
10 years
2 894.506 693.00
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 31/03/14 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 31/12/11 |
| Chief Tech/Sci/R&D Officer | 69 | 31/03/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 31/05/16 | |
Jean-Luc Butel
BRD | Director/Board Member | 67 | 31/05/16 |
Ian Clark
BRD | Director/Board Member | 62 | 31/12/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 24.44% | 14 M€ | +18.17% | ||
| 3.80% | 1,581 M€ | +26.97% | ||
| 3.43% | 243 M€ | +23.30% | ||
| 3.26% | 57 M€ | +27.82% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/07/24 | 4,285 | -0.56% | 2 737 100 |
| 17/07/24 | 4,309 | +1.63% | 3,099,700 |
| 16/07/24 | 4,240 | -1.35% | 3,177,000 |
| 12/07/24 | 4,298 | -0.32% | 3,916,000 |
| 11/07/24 | 4,312 | +1.46% | 5,195,400 |
Delayed Quote Japan Exchange, July 18, 2024 at 07:00 am
More quotes
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
Pharmaceuticals
Calendar
31/07/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,309
JPY
Average target price
4,730
JPY
Spread / Average Target
+9.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.70% | 43.61B | |
| +55.35% | 815B | |
| +32.17% | 597B | |
| -0.10% | 377B | |
| +15.47% | 319B | |
| +13.10% | 310B | |
| +16.13% | 247B | |
| +14.21% | 228B | |
| +16.54% | 180B | |
| +4.31% | 170B |
- Stock Market
- Equities
- 4502 Stock
